Innovation in Genetic Medicines

We develop precision nucleic acid therapies addressing key clinical unmet needs through strategic development partnerships.

Pipeline/Partnership
Screening
Vaccines / Undisclosed
Immuno-oncology gene therapy / Entos JV OncoSenX
p53-targeted suicide gene therapy / Entos JV OncoSenX
Program/Partner
Preclinical
Oncology
Discovery
P1
P2
P3
8 undisclosed programs / Undisclosed
Senolytic / Oisin
Age Related Diseases
Undisclosed / Undisclosed
Auto Immune
Metastasis / Internal
2 undisclosed programs / Undisclosed
Atherosclerosis / Repair Bio
Internal
Vaccines
Undisclosed
8 undisclosed programs
Undisclosed
Undisclosed
Undisclosed
Oisin
Immuno-oncology gene therapy
Entos JV OncoSenX
p53-targeted suicide gene therapy
Entos JV OncoSenX
Program
Partner
Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3
Oncology
Atherosclerosis
Senolytic
Repair Bio
2 undisclosed programs
Age-related Diseases
Undisclosed
Auto Immune
Metastasis
Scr
Vaccines / Undisclosed
Oncology
Immuno-oncology gene therapy / Entos JV OncoSenX
p53-targeted suicide gene therapy / Entos JV OncoSenX
Program/Partner
Pre
Dis
P1
P2
P3
8 undisclosed programs / Undisclosed
Age-related Diseases
Senolytic / Oisin
Auto Immune
Undisclosed / Undisclosed
Metastasis / Internal
2 undisclosed programs / Undisclosed
Atherosclerosis / Repair Bio
Scr
Pre
P1
P2
P3
p53-targeted suicide gene therapy / Entos JV OncoSenX
Immuno-oncology gene therapy /
Entos JV OncoSenX
Vaccines / Undisclosed
8 undisclosed programs / Undisclosed
Metastasis / Internal
Dis
Oncology
Auto Immune
Age-related Diseases
Undisclosed / Undisclosed
Senolytic / Oisin
Atherosclerosis / Repair Bio
2 undisclosed programs / Undisclosed
Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Email: info@entospharma.com
Phone: 1-780-862-7445
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.